Madrigal Pharmaceuticals Inc (MDGL) Directors and Executive Officers

Officers & Directors

Directors:

- Julian C. Baker
- Rebecca Taub, M.D.
- Paul A. Friedman, M.D.
- Fred B. Craves, Ph.D.
- Richard S. Levy, M.D.
- James M. Daly
- William J. Sibold
- Raymond Cheong
- Kenneth M. Bate

Executives:

- William J. Sibold (President and Chief Executive Officer)
- Alex G. Howarth (Chief Financial Officer - Principal Accounting and Financial Officer) ,

Madrigal Pharmaceuticals Inc currently has 915 employees.

News about Madrigal Pharmaceuticals Inc Key Personnel

Madrigal Pharmaceuticals Appoints New Leaders to Navigate Financial Challenges and Enhance Clinical Development Focus,

Madrigal Pharmaceuticals Strengthens Leadership Team Amid Financial ChallengesIntroductionMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company renowned for its focus on developing novel therapeutics for nonalcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatohepatitis (MASH), has made significant strides in fortifying its leadership team amidst recent financial challenges. On October 1, 2024, the company welcomed Dr. Michael R. Charlton as their Senior Vice President of Clinical Development. This strategic move comes at a critical juncture as Madrigal navigates a tumultuous financial landscape while striving for innovation in its research and development efforts....

Madrigal Pharmaceuticals’ Appointment of Shannon Kelley as General Counsel Sets Stage for Legal Expertise Amidst Financial Challenges

Madrigal Pharmaceuticals, a prominent biopharmaceutical company striving to develo...

Madrigal Pharmaceuticals Announces New Leadership Team Amidst Challenging Financial Quarter

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has recently welcomed three key additions to its leadership team, aiming to bolster its pursuit of innovative therapeutics for nonalcoholic steatohepatitis (NASH). The company s latest hires include Mark Barrett as Chief Business Officer, Clint Wallace as Chief Human Resources Officer, and Tina Ventura as Chief Investor Relations Officer. However, these strategic appointments come at a time when Madrigal Pharmaceuticals is grappling with a decline in share prices and a significant net loss.
During the 12-month period ending in the third quarter of 2023, Madrigal Pharmaceuticals Inc recorded a cumulative net loss of $-347 million, resulting in a negative r...